The role of thyroid hormone in the pathophysiology of heart failure: Clinical evidence

Heart Failure Reviews

Volumn 15, Issue 2, 2010, Pages 155-169

  Galli E , ^a   Pingitore A , ^b   Iervasi, G ^b  

^a UNIVERSITY OF PISA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Heart failure; Low T3 syndrome; Thyroid hormones

Indexed keywords

LIOTHYRONINE; THYROTROPIN; THYROXINE; THYROID HORMONE;

DIASTOLE; DISEASE COURSE; FREE LIOTHYRONINE INDEX; GENOMICS; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART RATE; HOMEOSTASIS; HUMAN; LIOTHYRONINE BLOOD LEVEL; LOW TRIIODOTHYRONINE SYNDROME; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SYNDROME; SYSTEMIC VASCULAR RESISTANCE; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; BLOOD; DRUG EFFECT; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HYPOTHYROIDISM; METABOLISM;

HEART FAILURE; HUMANS; HYPOTHYROIDISM; PROGNOSIS; THYROID HORMONES; TRIIODOTHYRONINE; VENTRICULAR FUNCTION; VENTRICULAR REMODELING;

EID: 76849089510     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-008-9126-6     Document Type: Review

References (144)

1. Jessup M, Brozena S (2003) Heart failure. N Engl J Med 348:2007-2018. doi:10.1056/NEJMra021498
2. Francis GS (2001) Pathophysiology of chronic heart failure. Am J Med 110(Suppl 7A):37S-46S. doi:10.1016/S0002-9343(98) 00385-4
3. Mann DL (1999) Mechanisms and models in heart failure-a combinatorial approach. Circulation 100:999-1008
4. Packer M (1992) The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. Am J Cardiol 20:248-254
5. Bleumink GS, Knetsch AM, Sturkenboom MC et al (2004) Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 25:1614-1619. doi:10.1016/j.ehj.2004. 06.038
6. Klein I, Ojamaa K (2004) Thyroid hormone and the cardiovascular system. N Engl J Med 244:501-507
7. Kahaly GJ, Dillmann WH (2005) Thyroid hormone action in the heart. Endocr Rev 26:704-728. doi:10.1210/er.2003-0033
8. Klein I, Danzi S (2007) Thyroid disease and the heart. Circulation 116:1725-1735. doi:10.1161/CIRCULATIONAHA.106. 678326
9. Iervasi G, Molinaro S, Landi P et al (2007) Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 167:1526-1532. doi:10.1001/archinte. 167.14.1526
10. Hamilton MA, Stevenson LW, Luu M et al (1990) Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol 16:91-95
11. Ascheim DD, Hryniewicz K (2002) Thyroid hormone metabolism in patients with congestive heart failure: the low triiodothyronine state. Thyroid 12:511-515. doi:10.1089/10507 2502760143908
12. Iervasi G, Pingitore A, Landi P et al (2003) Low-T3 syndrome-a strong prognostic predictor of death in patients with heart disease. Circulation 107:708-713. doi:10.1161/01.CIR.00000 48124.64204.3F
13. Pingitore A, Landi P, Taddei MC et al (2005) Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med 118:132-136. doi:10.1016/j.amjmed.2004.07.052
14. Opasich C, Pacini F, Ambrosino N et al (1996) Sick euthyroid syndrome in patients with moderate-to-severe chronic heart failure. Eur Heart J 17:1860-1866
15. Kozdag G, Ural D, Vural A et al (2005) Relation between free triiodothyronine/free thyroxine ratio, echocardiographic parameters and mortality in dilated cardiomyopathy. Eur J Heart Fail 7:113-118. doi:10.1016/j.ejheart.2004.04.016
16. Pingitore A, Iervasi G, Barison A et al (2006) Early activation of an altered thyroid hormone profile in asymptomatic or mildly symptomatic idiopathic left ventricular dysfunction. J Card Fail 12:520-526. doi:10.1016/j.cardfail. 2006.05.009
17. Pilo A, Iervasi G, Vitek F et al (1990) Thyroidal and peripheral production of 3, 5, 30-triiodothyronine in humans by mental analysis. Am J Physiol 258:E715-E726
18. Yen PM (2001) Physiological and molecular basis of thyroid hormone action. Physiol Rev 81:1097-1142
19. Bianco AC, Salvatore D, Gereben B et al (2002) Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23:38-89. doi: 10.1210/er.23.1.38
20. Everts ME, Verhoeven FA, Bezstarosti K et al (1996) Uptake of thyroid hormones in neonatal rat cardiac myocytes. Endocrinology 137:4235-4242. doi:10.1210/en.137.10.4235
21. Sabatino L, Iervasi G, Ferrazzi P et al (2000) A study of iodothyronine 50-monodeiodinase activities in normal and pathological tissues in man and their comparison with activities in rat tissues. Life Sci 68:191-202. doi:10.1016/S0024-3205 (00)00929-932
22. Wassen FW, Schiel AE, Kuiper GG et al (2002) Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure. Endocrinology 143:2812-2815. doi:10.1210/en.143. 7.2812
23. Simonides WS, Mulcahey MA, Redout EM et al (2008) Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats. J Clin Invest 118:975-983
24. Brent GA (1994) The molecular basis of thyroid hormone action. N Engl J Med 31:847-853. doi:10.1056/NEJM1994 09293311306
25. Davis PJ, Davis FB (2002) Nongenomic actions of thyroid hormone on the heart. Thyroid 12:459-466. doi:10.1089/10507 2502760143827
26. Wrutniak-Cabello C, Casas F, Cabello G (2001) Thyroid hormone action in mitochondria. J Mol Endocrinol 26:67-77. doi: 10.1677/jme.0.0260067
27. Bassett JH, Harvey CB, Williams GR (2003) Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions. Mol Cell Endocrinol 213:1-11. doi:10.1016/j.mce. 2003.10.033
28. Lazar MA (1993) Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev 14:184-193. doi:10.1210/er. 14.2.184
29. Wu Y, Koenig RJ (2000) Gene regulation by thyroid hormone. Trends Endocrinol Metab 11:207-211. doi:10.1016/S1043-2760(00)00263-270
30. Shibusawa N, Hollenberg AN, Wondisford FE (2003) Thyroid hormone receptor DNA binding is required for both positive and negative gene regulation. J Biol Chem 278:732-738. doi: 10.1074/jbc.M207264200
31. Lazar MA (2003) Thyroid hormone action: a binding contract. J Clin Invest 112:497-499
32. Davis PJ, Shih A, Lin HY et al (2000) Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR. J Biochem 275:38032-38039
33. Frank KF, Bölck B, Erdmann E et al (2003) Sarcoplasmic reticulum Ca2 ? -ATPase modulates cardiac contraction and relaxation. Cardiovasc Res 57:20-27. doi:10.1016/S0008-6363 (02)00694-696
34. Koss KL, Kranias EG (1996) Phospholamban: a prominent regulator of myocardial contractility. Circ Res 79:1059-1063
35. Ojamaa K, Petrie JF, Balkman C (1994) Posttranscriptional modification of myosin heavy-chain gene expression in the hypertrophied rat myocardium. Proc Natl Acad Sci USA 91:3468-3472. doi:10.1073/pnas.91.8.3468
36. Klein I, Ojamaa K (2001) Thyroid hormone targeting the vascular smooth muscle cell. Circ Res 88:260-261
37. Ojamaa K, Klemperer JD, Klein I (1996) Acute effects of thyroid hormone on vascular smooth muscle. Thyroid 6:505-512
38. Colantuoni A, Marchiafava PL, Lapi D et al (2005) Effects of tetraiodothyronine and triiodothyronine on hamster cheek pouch microcirculation. Am J Physiol Heart Circ Physiol 288:H1931-H1936. doi:10.1152/ajpheart.00931. 2004
39. Mizuma H, Murakami M, Mori M (2001) Thyroid hormone activation in human vascular smooth muscle cells: expression of type II iodothyronine deiodinase. Circ Res 88:313-318
40. Fukuyama K, Ichiki T, Takeda K et al (2003) Downregulation of vascular angiotensin II type 1 receptor by thyroid hormone. Hypertension 41:598-603. doi:10.1161/01.HYP.0000056524.35 294.80
41. Fommei E, Iervasi G (2002) The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. J Clin Endocrinol Metab 87:1996-2000. doi:10.1210/jc.87.5.1996
42. Dernellis J, Panaretou M (2002) Effects oh thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidism. Am Heart J 143:718-724. doi:10.1067/ mhj.2002.120766
43. Biondi B, Palmieri EA, Lombardi G et al (2002) Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. J Clin Endocrinol Metab 87:968-974. doi:10.1210/jc.87.3.968
44. Kimura K, Shinozaki Y, Jujo S (2006) Triiodothyronine acutely increases blood flow in the ventricles and kidneys of anesthesized rabbits. Thyroid 16:357-360. doi:10.1089/thy.2006.16.357
45. Yoneda K, Takasu N, Higa S et al (1998) Direct effects of thyroid hormones on rat coronary artery: nongenomic effects of triiodothyronine and thyroxine. Thyroid 8:609-613
46. Kasahara T, Tsunekawa K, Seki K et al (2006) Regulation of iodothyronine deiodinase and roles of thyroid hormones in human coronary artery smooth muscle cells. Atherosclerosis 18:207-214. doi:10.1016/j.atherosclerosis.2005.07.018
47. Baycan S, Erdogan D, Caliskan M et al (2007) Coronary flow reserve is impaired in subclinical hypothyroidism. Clin Cardiol 30:562-566. doi:10.1002/clc.20132
48. Danzi S, Klein I (2004) Thyroid hormone and the cardiovascular system. Minerva Endocrinol 29:139-150
49. Bengel FM, Nekolla S, Ziegler SI et al (2000) Effect of thyroid hormones on cardiac function and oxidative metabolism assessed noninvasively by positron emission tomography and magnetic resonance imaging. J Clin Endocrinol Metab 85:1822-1827. doi:10.1210/jc.85.5.1822
50. Biondi B, Palmieri EA, Lombardi G et al (2002) Subclinical hypothyroidism and cardiac function. Thyroid 12:505-510. doi: 10.1089/105072502760143890
51. Ripoli A, Pingitore A, Favilli B et al (2005) Does subclinical hypothyroidism affect cardiac pump performance? Evidence from a magnetic resonance imaging study. J Am Coll Cardiol 45:439-445. doi:10.1016/j.jacc.2004. 10.044
52. Rodondi N, Newman AB, Vittinghoff E et al (2005) Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med 165:2460-2466. doi: 10.1001/archinte.165.21.2460
53. Kahaly GJ (2000) Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid 10:665-679. doi:10.1089/ 10507250050137743
54. Taddei S, Caraccio N, Virdis A et al (2003) Impaired endothelium- dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 88:3731-3737. doi:10.1210/jc.2003-030039
55. Monzani F, Caraccio N, Kozàkowà M et al (2004) Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 89:2099-2106. doi:10.1210/jc.2003-031669
56. Caraccio N, Ferrannini E, Monzani F (2002) Lipoprotein profile in subclinical hypothyroidism: response to replacement, a randomized placebocontrolled study. J Clin Endocrinol Metab 87:1533-1538. doi:10.1210/jc.87.4.1533
57. Chen HS, Wu TE, Jap TS et al (2007) Subclinical hypothyroidism is a risk factor for nephropathy and cardiovascular diseases in Type 2 diabetic patients. Diabet Med 24:1336-1344. doi:10.1111/j.1464-5491.2007.02270.x
58. ChoncholM, LippiG, SalvagnoG, ZoppiniG,Muggeo M, Targher G (2008) Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. Clin J Am Soc Nephrol 5:1296-1300
59. Hak AE, Pols HA, Visser TJ et al (2000) Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Ann Intern Med 15(132):270-278
60. Rodondi N, Aujesky D, Vittinghoff E et al (2006) Subclinical hypothyroidism and the risk of coronary heart disease: a metaanalysis. Am J Med 119:541-551. doi:10.1016/j.amjmed.2005. 09.028
61. Sawin CT, Geller A, Wolf PA et al (1994) Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older patients. N Engl J Med 331:1249-1252. doi:10.1056/NEJM199 411103311901
62. Osman F, Gammage MD, Sheppard MC et al (2002) Clinical review 142: cardiac dysrhythmias and thyroid dysfunction: the hidden menace? J Clin Endocrinol Metab 87:963-967. doi: 10.1210/jc.87.3.963
63. Petretta M, Bonaduce D, Spinelli L et al (2001) Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. Eur J Endocrinol 145:691-696. doi:10.1530/eje.0.1450691
64. Biondi B, Palmieri EA, Fazio S et al (2000) Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab 85:4701-4705. doi:10.1210/jc.85.12. 4701
65. Biondi B, Palmieri EA, Lombardi G et al (2002) Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med 137:904-914
66. Mercuro G, Panzuto MG, Bina A et al (2000) Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab 85:159-164. doi:10.1210/jc.85.1.159
67. Parle JV, Maisonneuve P, Sheppard MC et al (2001) Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358:861-865. doi:10.1016/S0140-6736(01) 06067-6
68. Surks MI, Ortiz E, Daniels GH et al (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. J Am Med Assoc 291:228-238. doi:10.1001/ jama.291.2.228
69. Singh S, Duggal J, Molnar J et al (2008) Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis. Int J Cardiol 125:41-48. doi:10.1016/j.ijcard.2007.02.027
70. Cappola AR, Fried LP, Arnold AM et al (2006) Thyroid status, cardiovascular risk, and mortality in older adults. J Am Med Assoc 295:1033-1041. doi:10.1001/jama.295.9.1033
71. Imaizumi M, Akahoshi M, Ichimaru S et al (2004) Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab 89:3365-3370. doi: 10.1210/jc.2003-031089
72. Walsh JP, Bremner AP, Bulsara MK et al (2005) Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 165:2467-2472. doi:10.1001/archinte.165. 21.2467
73. Asvold BO, Bjøro T, Nilsen TI et al (2008) Thyrotropin levels and risk of fatal coronary heart disease: the HUNT Study. Arch Intern Med 168:855-860. doi:10.1001/archinte.168.8.855
74. Eisenstein Z, Hagg S, Vagenakis AG et al (1978) Effect of starvation on the production and peripheral metabolism of 3, 30, 50-triiodothyronine in euthyroid obese subjects. J Clin Endocrinol Metab 47:889-893
75. Eber B, Schumacher M, Langsteger W et al (1995) Changes in thyroid hormone parameters after acute myocardial infarction. Cardiology 86:152-156
76. Friberg L, Werner S, Eggertsen G et al (2002) Rapid downregulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina? Arch Intern Med 162:1388-1394. doi:10.1001/archinte.162. 12.1388
77. Holland FW 2nd, Brown PS Jr, Weintraub BD et al (1991) Cardiopulmonary bypass and thyroid function: a "euthyroid sick syndrome". Ann Thorac Surg 52:46-50
78. Klemperer JD, Klein I, Gomez M et al (1955) Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med 333:1522-1527. doi:10.1056/NEJM199512073332302
79. Murzi B, Iervasi G, Masini S et al (1995) Thyroid hormones homeostasis in pediatric patients during and after cardiopulmonary bypass. Ann Thorac Surg 59:481-485. doi: 10.1016/00 03-4975(94)00879-C
80. Sabatino L, Cerillo AG, Ripoli A et al (2002) Is the low triiodothyronine state a crucial factor in determining the outcome of coronary artery bypass patients? Evidence from a clinical pilot study. J Endocrinol 175:577-586. doi:10.1677/joe.0.17 50577
81. Wartofsky L, Barman KD (1982) Alteration in thyroid function in patients with systemic illness: the "euthyroid sick syndrome". Endocr Rev 3:164-217
82. Peeters RP, Wouters PJ, Kaptein E et al (2003) Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 88:3202-3211. doi:10.1210/jc.2002-022013
83. Chopra IJ, Wu SY, Teco GN et al (1992) A radioimmunoassay for measurement of 3, 5, 30-triiodothyronine sulfate: studies in thyroidal and nonthyroidal diseases, pregnancy, and neonatal life. J Clin Endocrinol Metab 1:189-194. doi:10.1210/jc.75.1.189
84. Peeters RP, Kester MH, Wouters PJ et al (2005) Increased thyroxine sulfate levels in critically ill patients as a result of a decreased hepatic type I deiodinase activity. J Clin Endocrinol Metab 90:6460-6465. doi:10.1210/jc.2005-0866
85. Duntas LH, Nguyen TT, Keck FS et al (1999) Changes in metabolism of TRH in euthyroid sick syndrome. Eur J Endocrinol 141:337-341. doi:10.1530/eje.0. 1410337
86. Boelen A, Platvoet-Ter Schiphorst MC, Wiersinga WM (1993) Association betxeen serum interleukin-6 and serum 3, 5, 30-triiodothyronine in nonthyroidal illness. J Clin Endocrinol Metab 77:1695-1699. doi:10.1210/jc.77.6.1695
87. Stouthard JM, Van der Poll T, Ebdert E et al (1994) Effects of acute and chronic IL-6 administration on thyroid hormone metabolism in humans. J Clin Endocrinol Metab 79:1342-1346. doi:10.1210/jc.79.5.1342
88. Bartalena L, Bogazzi F, Brogioni S et al (1998) Role of cytokines in the pathogenesis of the euthyroid sick syndrome. Eur J Endocrinol 138:603-614. doi:10.1530/eje.0.1380603
89. Kimura T, Kanda T, Kotajima N et al (2000) Involvment of circulating IL-6 and its receptor in the development o euthyroid sick syndrome in patients with acute myocardial infarction. Eur J Endocrinol 143:179-184. doi:10.1530/eje.0. 1430179
90. Reichlin S (1993) Neuroendocrine-Immune interactions. N Engl J Med 329:1246-1253. doi:10.1056/NEJM199310213291708
91. Sylvén C, Jansson E, Sotonyi P et al (1996) Cardiac nuclear hormone receptor mRNA in heart failure in man. Life Sci 59:1917-1922. doi:10.1016/S0024-3205(96)00539-5
92. Kinugawa K, Yonekura K, Ribeiro RC et al (2001) Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ Res 89:591-598. doi: 10.1161/hh1901.096706
93. Liu Y, Redetzke RA, Said S et al (2008) Serum thyroid hormone levels may not accurately reflect thyroid tissue levels and cardiac function in mild hypothyroidism. Am J Physiol Heart Circ Physiol 294:H2137-H2143. doi:10.1152/ajpheart.01379.2007
94. Sabatino L, Gliozheni E, Molinaro S et al (2007) Thyroid hormone receptor and IGF1/IGFR systems: possible relations in the human heart. Biomed Pharmacother 61:457-462. doi:10.1016/ j.biopha.2007.04.002
95. Belke DD, Gloss B, Swanson EA et al (2007) Adeno-associated virus-mediated expression of thyroid hormone receptor isoforms-alpha1 and -beta1 improves contractile function in pressure overload-induced cardiac hypertrophy. Endocrinology 148:2870-2877. doi:10.1210/en.2007-0009
96. Mai W, Janier MF, Allioli N et al (2004) Thyroid hormone receptor alpha is a molecular switch of cardiac function between fetal and postnatal life. Proc Natl Acad Sci USA 101:10332-10337. doi:10.1073/pnas.0401843101
97. Kinugawa K, Minobe WA, Wood WM et al (2001) Signaling pathways responsible for fetal gene induction in the failing human heart: evidence for altered thyroid hormone receptor gene expression. Circulation 103:1089-1094
98. Izumo S, Lompré AM, Matsuoka R et al (1987) Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals. J Clin Invest 79:970-977. doi: 10.1172/JCI112908
99. Colucci WS (1997) Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 80:15L-25L. doi:10.1016/S00 02-9149(97)00845-X
100. Haghighi K, Schmidt AG, Hoit BD et al (2001) Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. J Biol Chem 276:24145-24152. doi: 10.1074/jbc.M102403200
101. Razeghi P, Young ME, Alcorn JL et al (2001) Metabolic gene expression in fetal and failing human heart. Circulation 104:2923-2931. doi:10.1161/hc4901. 100526
102. Katzeff HL, Powell SR, Ojamaa K (1997) Alterations in cardiac contractility and gene expression during low-T3 syndrome: prevention with T3. Am J Physiol 273:E951-E956
103. Ladenson PW, Sherman SI, Baughman KL et al (1992) Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci USA 89:5251-5255. doi:10.1073/pnas.89.12. 5251
104. Forini F, Paolicchi A, Pizzorusso T et al (2001) 3, 5, 30-Triiodothyronine deprivation affects phenotype and intracellular [Ca2 ?]i of human cardiomyocytes in culture. Cardiovasc Res 51:322-330. doi:10.1016/S0008- 6363(01)00287-5
105. Pieske B, Kretschmann B, Meyer M et al (1995) Alteration in intracellular calcium handling associated with the inverse force frequency relation in human dilated cardiomyopathy. Circulation 92:1169-1178
106. Hein S, Kostin S, Heling A et al (2000) The role of cytoskeleton in heart failure. Cardiovasc Res 45:273-278. doi:10.1016/ S0008-6363(99)00268-270
107. Pantos C, Xinaris C, Mourouzis I et al (2007) Thyroid hormone changes cardiomyocyte shape and geometry via ERK signaling pathway: potential therapeutic implications in reversing cardiac remodeling? Mol Cell Biochem 297:65-72. doi:10.1007/ s11010-006-9323-9333
108. Lee HW, Klein LE, Raser J et al (1998) An activator protein-1 (AP-1) response element on pro alpha1(l) collagen gene is necessary for thyroid hormone-induced inhibition of promoter activity in cardiac fibroblasts. J Mol Cell Cardiol 30:2495-2506. doi:10.1006/jmcc.1998.0811
109. Yao J, Eghbali M (1992) Decreased collagen mRNA and regression of cardiac fibrosis in the ventricular myocardium of the tight skin mouse following thyroid hormone treatment. Cardiovasc Res 26:603-607. doi:10.1093/cvr/26.6.603
110. Wong K, Boheler KR, Petrou M (1997) Pharmacological modulation of pressure-overload cardiac hypertrophy: changes in ventricular function, extracellular matrix, and gene expression. Circulation 96:2239-2246
111. Janicki JS, Brower GL, Gardner JD et al (2004) The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling. Heart Fail Rev 9:33-42. doi: 10.1023/B:HREV.0000011392.03037.7e
112. Khalife WI, Tang YD, Kuzman JA et al (2005) Treatment of subclinical hypothyroidism reverses ischemia and prevents myocyte loss and progressive LV dysfunction in hamsters with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289:H2409-H2415. doi:10.1152/ajpheart.00483.2005
113. Ryoke T, Gu Y, Ikeda Y et al (2002) Apoptosis and oncosis in the early progression of left ventricular dysfunction in the cardiomyopathic hamster. Basic Res Cardiol 97:65-75. doi: 10.1007/s395-002-8389-4
114. Tomanek RJ, Schatteman GC (2000) Angiogenesis: new insights and therapeutic potential. Anat Rec 261:126-135. doi:10.1002/1097-0185(20000615)261: 3\126::AID-AR7[3.0. CO;2-4
115. Wang X, Zheng W, Christensen LP et al (2003) DITPA stimulates bFGF, VEGF, angiopoietin, and Tie-2 and facilitates coronary arteriolar growth. Am J Physiol Heart Circ Physiol 284:H613-H618
116. Zheng W, Weiss RM, Wang X et al (2004) DITPA stimulates arteriolar growth and modifies myocardial postinfarction remodeling. Am J Physiol Heart Circ Physiol 286:H1994-H2000. doi:10.1152/ajpheart.00991.2003
117. Davis FB, Mousa SA, O'Connor L et al (2004) Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 94:1500-1506. doi: 10.1161/01.RES.0000130784.90237.4a
118. Van Den Heuvel AF, Van Veldhuisen DJ, Van Der Wall EE et al (2000) Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 35:19-28. doi:10.1016/S0735-1097(99)00499-4
119. Neglia D, Michelassi C, Trivieri MG et al (2002) Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 15:186-193. doi:10.1161/hc02 02.102119
120. Pantos C, Malliopoulou V, Varonos DD et al (2003) Thyroid hormone and phenotypes of cardioprotection. Basic Res Cardiol 99:101-120. doi:10.1007/s00395-003-0449-0
121. Liu Q, Clanachan AS, Lopaschuk GD (1998) Acute effects of triiodothyronine on glucose and fatty acid metabolism during reperfusion of ischemic rat hearts. Am J Physiol 275:E392-E399
122. Chen YF, Kobayashi S, Chen J et al (2008) Short term triiodo-Lthyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats. J Mol Cell Cardiol 44:180-187. doi:10.1016/j.yjmcc.2007.09. 009
123. Pantos C, Malliopoulou V, Mourouzis I et al (2003) Thyroxine pretreatment increases basal myocardial heat-shock protein 27 expression and accelerates translocation and phosphorylation of this protein upon ischaemia. Eur J Pharmacol 478:53-60. doi: 10.1016/j.ejphar.2003.08.030
124. Pantos C, Malliopoulou V, Mourouzis I et al (2006) Hyperthyroid hearts display a phenotype of cardioprotection against ischemic stress: a possible involvement of heat shock protein 70. Horm Metab Res 38:308-313. doi:10.1055/s-2006-925404
125. Giannessi D, Colotti C, Maltinti M et al (2007) Circulating heat shock proteins and inflammatory markers in patients with idiopathic left ventricular dysfunction: their relationships with myocardial and microvascular impairment. Cell Stress Chaperones 12:265-274. doi:10.1379/CSC-272.1
126. Emdin M, Passino C, Prontera C et al (2004) Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med 42:627-636. doi:10.1515/CCLM.2004.108
127. Pingitore A, Iervasi G (2008) Triiodothyronine (T3) effects on cardiovascular system in patients with heart failure. Recent Patents Cardiovasc Drug Discov 3:19-27
128. Chopra IJ (1997) Euthyroid sick syndrome: is it a misnomer? J Clin Endocrinol Metab 82:329-334. doi:10.1210/jc.82.2.329
129. De Groot LJ (1999) Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab 84:151-164. doi:10.1210/jc.84.1.151
130. Klein I, Danzi S (2008) Thyroid hormone treatment to mend a broken heart. J Clin Endocrinol Metab 93:1172-1174. doi: 10.1210/jc.2008-0291
131. Pantos C, Mourouzis I, Markakis K et al (2007) Thyroid hormone attenuates cardiac remodeling and improves hemodynamics early after acute myocardial infarction in rats. Eur J Cardiothorac Surg 32:333-339. doi:10.1016/j.ejcts. 2007.05.004
132. Brokhin M, Klein I (2005) Low T3 syndrome in a patient with acute myocarditis. Clin Cornerstone 7(Suppl 2):S28-S29. doi: 10.1016/S1098-3597(05) 80057-2
133. Malik FS, Mehra MR, Uber PA et al (1999) Intravenous thyroid hormone supplementation in heart failure with cardiogenic shock. J Card Fail 5:31-37. doi:10.1016/S1071-9164(99)90022-32
134. Klemperer JD, Zelano J, Helm RE et al (1995) Triiodothyronine improves left ventricular function without oxygen wasting effects after global hypothermic ischemia. J Thorac Cardiovasc Surg 109:457-465. doi:10.1016/S0022- 5223(95)70276-8
135. Klemperer JD, Klein IL, Ojamaa K et al (1996) Triiodothyronine therapy lowers the incidence of atrial fibrillation after cardiac operations. Ann Thorac Surg 61:1323-1327. doi: 10.1016/0003-4975(96)00102-6
136. Moruzzi P, Doria E, Agostoni PG et al (1994) Usefulness of Lthyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy. Am J Cardiol 73:374-378. doi: 10.1016/0002-9149(94)90011-6
137. Moruzzi P, Doria E, Agostoni PG (1996) Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy. Am J Med 101:461-467. doi:10.1016/S0002-9343(96)00281-1
138. Hamilton MA, Stevenson LW, Fonarow GC et al (1998) Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol 81:443-447. doi:10.1016/S0002-9149(97)00950-8
139. Pingitore A, Galli E, Barison A et al (2008) Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab 93:1351-1358. doi:10.1210/jc.2007-2210
140. Brenta G, Danzi S, Klein I (2007) Potential therapeutic applications of thyroid hormone analogs. Nat Clin Pract Endocrinol Metab 3:632-640. doi:10.1038/ncpendmet0590
141. Pennock GD, Raya TE, Bahl JJ et al (1992) Cardiac effects of 3, 5-diiodothyropropionic acid, a thyroid hormone analog with inotropic selectivity. J Pharmacol Exp Ther 263:163-169
142. Morkin E, Pennock GD, Spooner PH et al (2002) Clinical and experimental studies on the use of 3, 5-diiodothyropropionic acid, a thyroid hormone analogue, in heart failure. Thyroid 12:527-533. doi:10.1089/105072502760143935
143. Morkin E, Ladenson P, Goldman S et al (2004) Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: past, present and future prospects. J Mol Cell Cardiol 37:1137-1146
144. Trivieri MG, Oudit GY, Sah R et al (2006) Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction. Proc Natl Acad Sci USA 103:6043-6048. doi:10.1073/pnas. 0601072103